Supernus Pharmaceuticals, Inc.
Common Stock · USD · NASDAQ
Price
$47.44
Cap
$221.33B
Earnings
—
30d Trend
-5.5%
BRAIN47 SIGNAL
Raw weighted: 47×Macro 0.99 (−1%)=47
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Moderate long-term case — not compelling enough for a multi-year commitment
BRAIN47'S ASSESSMENT
I rate Supernus Pharmaceuticals, Inc. at 47/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 77/100. I classify this as a growth position with the strongest thesis on a long-term horizon.
DETAILED ANALYSIS
Moderate long-term case — not compelling enough for a multi-year commitment. Momentum (77) and Quality (46) are the primary strengths. I note that fundamentals is the weakest area at 32/100 — this warrants monitoring. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.